About Valion Bio Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://tivichealth.com
Frequently Asked Questions
What is the 52-week range for VBIO?
The 52-week high is $32.5 and the 52-week low is $2.05.
What is the P/E ratio for VBIO?
The P/E ratio data is currently unavailable.
What is the dividend yield for VBIO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -97.34%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1557.26%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.34.
Latest VBIO News
Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development Pathway
Valion Bio and Shear Kershman Laboratories have completed formulation work for oral mucosal Entolimod, with the next study set to determine whether the needle-free approach can deliver measurable levels of the biologic into the bloodstream. Key Investor TakeawaysValion Bio (NASDAQ:VBIO) has successfully formulated Entolimod using Shear Kershman Laboratories’ BioViscid drug-delivery platform, establishing a potential second development pathway alongside injectable Entolimod.
Wednesday's pre-market session: top gainers and losers
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
The milestone advances a potential second delivery pathway for Entolimod, which has historically been administered by injection. The BioViscid™-Entolimod formulation is designed to deliver Entolimod through the lining of the mouth.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix (NASDAQ:ONCO) stock rose
Wondering what's happening in today's pre-market session?
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunitiesSAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced decisive changes to its executive leadership team and Board of Directors (the "Board"). These leadership transitions are intended to strengthen organizational alignment and support focused exe
Valion Bio Appoints Dean Zikria Interim CEO, Thomas Jensen As Board Chair
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced decisive changes to its executive leadership team and Board of Directors (the
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
Nasdaq confirms compliance with continued listing standard and closes the matterSAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / (Nasdaq:VBIO) ("Valion" or the "Company) announced today that it has received formal written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closi
Valion Bio Regains NASDAQ Compliance
Nasdaq confirms compliance with continued listing standard and closes the matterSAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company) announced
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Zikria Dean | +50,000 | - | - |
| 2026-09-18 | Wolf Lisa G | -4 | - | - |
| 2026-09-18 | Wolf Lisa G | -2 | $2.12 | $4 |
| 2026-09-18 | Wolf Lisa G | +4 | - | - |
| 2026-05-18 | Handley Michael K | -2,206 | - | - |
| 2026-05-18 | Handley Michael K | +2,206 | - | - |